Form 4: Y-mAbs Therapeutics Completes Merger, Goes Private
Statement of Changes in Beneficial Ownership (Form 4)
Y-mAbs Therapeutics, Inc. has completed its merger, becoming an indirect wholly-owned subsidiary of Stark International Lux, with shareholders receiving $8.60 per share in cash.
Summary
- Y-mAbs Therapeutics, Inc. completed its merger on September 16, 2025, transitioning into an indirect wholly-owned subsidiary of Stark International Lux.
- The merger involved a tender offer by Yosemite Merger Sub, Inc. for Y-mAbs common stock, followed by a merger into the Issuer.
- Shareholders, including reporting person Johan Wedell-Wedellsborg, received $8.60 per share in cash for their common stock.
- Restricted Stock Units (RSUs) held by the reporting person were cancelled and converted into a cash payment equal to the number of shares multiplied by the $8.60 merger consideration.
- Employee stock options were cancelled; those with an exercise price below $8.60 were converted into cash based on the difference between the merger consideration and the exercise price, while those with an exercise price equal to or above $8.60 were cancelled for no consideration.
Sentiment
Score: 7
Explanation: The sentiment is generally positive for the reporting person as they successfully monetized their equity holdings at a predetermined cash price. However, the cancellation of out-of-the-money options for no consideration represents a loss of potential future value. For the company, it signifies a transition to private ownership, which can be seen as a positive for strategic flexibility but removes public investment opportunities.
Positives
- Reporting person Johan Wedell-Wedellsborg received $8.60 per share in cash for 5,825 directly owned common shares.
- WG Biotech ApS, majority-owned by the reporting person, received $8.60 per share in cash for 4,559,233 common shares.
- Reporting person received cash for 25,080 Restricted Stock Units (RSUs) at $8.60 per unit.
- Reporting person received cash for in-the-money employee stock options, including 36,000 options with an exercise price of $4.38, 13,950 options with an exercise price of $8.13, and 33,450 options with an exercise price of $4.51.
Negatives
- Reporting person's employee stock options with an exercise price equal to or exceeding the $8.60 merger consideration were cancelled for no value, including options with exercise prices of $11.16, $21.45, $48.67, $37.53, $16.64, and $12.01.
- Reporting person and WG Biotech ApS no longer hold any beneficial ownership in Y-mAbs Therapeutics, Inc., eliminating future equity participation.
- The company's shares are no longer publicly traded, removing investment opportunities in the public market.
Future Outlook
The filing reports a completed merger, resulting in Y-mAbs Therapeutics, Inc. becoming an indirect wholly-owned subsidiary. As such, it no longer has a public future outlook or publicly traded shares.
Industry Context
This filing reflects a specific corporate action (merger and privatization) for Y-mAbs Therapeutics, Inc. It does not provide broader industry trends or competitive analysis. Mergers and acquisitions are common in the biotechnology and pharmaceutical sectors, often driven by strategic consolidation or the acquisition of promising drug pipelines.
Related Party Transactions
- The disposal of 4,559,233 common shares by WG Biotech ApS, an entity majority-owned by the reporting person, is a transaction involving a related party as part of the broader merger.
Stakeholder Impact
- Shareholders: All public shareholders received $8.60 per share in cash, converting their equity into a liquid asset.
- Employees (with equity): Employees holding RSUs and in-the-money stock options received cash payments, while out-of-the-money options were cancelled.
- Company: Y-mAbs Therapeutics, Inc. transitioned from a publicly traded company to an indirect wholly-owned subsidiary, implying changes in operational and strategic oversight under new ownership.
Key Dates
| Date | Description |
|---|---|
| 2025-08-04 | Date of the Agreement and Plan of Merger. |
| 2025-09-16 | Date of earliest transaction; completion of the tender offer and merger, making Y-mAbs Therapeutics an indirect wholly-owned subsidiary. |
| 2025-09-18 | Date of signature for the Form 4 filing. |
| 2026-10-21 | Expiration date for employee stock options with an exercise price of $4.38. |
| 2028-04-24 | Expiration date for employee stock options with an exercise price of $11.16. |
| 2029-06-12 | Expiration date for employee stock options with an exercise price of $21.45. |
| 2030-06-23 | Expiration date for employee stock options with an exercise price of $48.67. |
| 2031-06-10 | Expiration date for employee stock options with an exercise price of $37.53. |
| 2032-07-15 | Expiration date for employee stock options with an exercise price of $16.64. |
| 2033-06-08 | Expiration date for employee stock options with an exercise price of $8.13. |
| 2034-06-11 | Expiration date for employee stock options with an exercise price of $12.01. |
| 2035-06-30 | Expiration date for employee stock options with an exercise price of $4.51. |
Keywords
Y-mAbs Therapeutics, YMAB, Merger, Tender Offer, SEC Form 4, Beneficial Ownership, Stock Options, RSUs, Insider Transaction, Going Private, Equity Disposal, Cash Consideration
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.